We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
(+22%)
Cap. Flow
+$284M
Cap. Flow
% of AUM
244.1%
Top 10 Holdings %
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.59M |
| 2 |
Biogen
BIIB
|
+$3.56M |
| 3 |
Cal-Maine
CALM
|
+$2.79M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.48M |
| 5 |
Apple
AAPL
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$4.11M |
| 2 |
Gilead Sciences
GILD
|
+$2M |
| 3 |
IBM
IBM
|
+$1.48M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$930K |
| 5 |
Expedia Group
EXPE
|
+$914K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.4% |
| 2 | Technology | 6.27% |
| 3 | Consumer Staples | 4.14% |
| 4 | Consumer Discretionary | 2.26% |
| 5 | Materials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NBIS
176
PUT
Nebius Group N.V.
NBIS
$45.1B
| $75K | 0.06% |
+35,000
| New | +$680K |
|
177
CALL
Post Holdings
POST
$3.94B
| $72K | 0.06% |
+16,808
| New | +$813K |
|
178
CALL
United Parcel Service
UPS
$100B
| $71K | 0.06% |
+20,000
| New | +$2.08M |
|
|
CLVS
179
DELISTED
Clovis Oncology, Inc.
CLVS
| $71K | 0.06% |
5,190
-2,620
| -34% | -$38.3K |
|
180
PUT
Eli Lilly
LLY
$1.05T
| $70K | 0.06% |
+140,000
| New | +$10.5M |
|
181
PUT
Herbalife
HLF
$1.24B
| $68K | 0.06% |
28,000
+19,600
| +233% | +$587K |
|
182
CALL
Best Buy
BBY
$18B
| $67K | 0.06% |
+50,000
| New | +$1.57M |
|
183
CALL
Five Below
FIVE
$11.2B
| $64K | 0.06% |
9,600
+200
| +2% | +$8.36K |
|
184
CALL
Jazz Pharmaceuticals
JAZZ
$15.5B
| $64K | 0.06% |
24,100
| – | – |
|
185
Rambus
RMBS
$11B
| $63K | 0.05% |
+5,200
| New | +$63.4K |
|
|
EXAS
186
CALL
DELISTED
Exact Sciences
EXAS
| $62K | 0.05% |
+97,500
| New | +$734K |
|
187
PUT
Microsoft
MSFT
$2.93T
| $62K | 0.05% |
+36,400
| New | +$1.89M |
|
188
ProQR Therapeutics
PRQR
$240M
| $61K | 0.05% |
12,523
| – | – |
|
189
CALL
ASML
ASML
$671B
| $60K | 0.05% |
6,200
-4,300
| -41% | -$418K |
|
190
Intel
INTC
$478B
| $60K | 0.05% |
1,831
-11,307
| -86% | -$354K |
|
|
191
PUT
ASML
ASML
$671B
| $59K | 0.05% |
+9,700
| New | +$944K |
|
192
CALL
Bausch Health
BHC
$1.8B
| $59K | 0.05% |
44,500
-92,500
| -68% | -$2.62M |
|
|
CYBR
193
CALL
DELISTED
CyberArk
CYBR
| $57K | 0.05% |
24,900
+6,600
| +36% | +$285K |
|
|
ATXS
194
DELISTED
Astria Therapeutics
ATXS
| $56K | 0.05% |
+251
| New | +$75.7K |
|
195
PUT
lululemon athletica
LULU
$13.2B
| $56K | 0.05% |
15,500
-4,500
| -23% | -$298K |
|
|
FLNA
196
PUT
Filana Therapeutics
FLNA
$51.2M
| $56K | 0.05% |
+10,714
| New | +$170K |
|
|
BLUE
197
DELISTED
bluebird bio
BLUE
| $55K | 0.05% |
+97
| New | +$54.9K |
|
198
CALL
Salesforce
CRM
$140B
| $54K | 0.05% |
+12,500
| New | +$981K |
|
199
PUT
Monster Beverage
MNST
$95.4B
| $54K | 0.05% |
70,800
-99,000
| -58% | -$2.39M |
|
200
CALL
Procter & Gamble
PG
$349B
| $54K | 0.05% |
+16,000
| New | +$1.31M |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2016 Portfolio in Review
As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.
- FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
- FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
- FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
- FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
- FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
- FT Options opened 171 new positions and closed 122 in Q2 2016.
- FT Options's portfolio value rose 22% quarter-over-quarter to $116M.
Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.